The efficacy of carmustine wafers for older patients with glioblastoma multiforme: Prolonging survival

Kaisorn L. Chaichana, Hasan Zaidi, Courtney Pendleton, Matthew J. McGirt, Rachel Grossman, Jon D. Weingart, Alessandro Olivi, Alfredo Quinones-Hinojosa, Henry Brem

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients. Methods: One hundred and thirty-three consecutive patients aged 65 years and older who underwent surgery for an intracranial primary (de novo) GBM from 1997-2007 were retrospectively reviewed. Among these 133 patients, 45 patients with carmustine wafer implantation were matched with 45 patients without implantation. These groups were matched for factors consistently shown to be associated with survival (age, Karnofsky performance scale, extent of resection, radiation therapy, and temozolomide). Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves. Variables with P<0.05 were considered statistically significant. Results: The mean (±standard deviation) age of the cohort was 73±5 years, and the median survival of the entire cohort was 5.9 months. Among patients with and without carmustine wafers, there were no significant differences in pre- and peri-operative variables. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007). Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers. Discussion: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.

Original languageEnglish (US)
Pages (from-to)759-765
Number of pages7
JournalNeurological Research
Volume33
Issue number7
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Carmustine
Glioblastoma
Survival
temozolomide
Karnofsky Performance Status

Keywords

  • Carmustine wafers
  • Elderly
  • GBM
  • Gliadel
  • Glioblastoma
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Chaichana, K. L., Zaidi, H., Pendleton, C., McGirt, M. J., Grossman, R., Weingart, J. D., ... Brem, H. (2011). The efficacy of carmustine wafers for older patients with glioblastoma multiforme: Prolonging survival. Neurological Research, 33(7), 759-765. https://doi.org/10.1179/1743132811Y.0000000006

The efficacy of carmustine wafers for older patients with glioblastoma multiforme : Prolonging survival. / Chaichana, Kaisorn L.; Zaidi, Hasan; Pendleton, Courtney; McGirt, Matthew J.; Grossman, Rachel; Weingart, Jon D.; Olivi, Alessandro; Quinones-Hinojosa, Alfredo; Brem, Henry.

In: Neurological Research, Vol. 33, No. 7, 09.2011, p. 759-765.

Research output: Contribution to journalArticle

Chaichana, KL, Zaidi, H, Pendleton, C, McGirt, MJ, Grossman, R, Weingart, JD, Olivi, A, Quinones-Hinojosa, A & Brem, H 2011, 'The efficacy of carmustine wafers for older patients with glioblastoma multiforme: Prolonging survival', Neurological Research, vol. 33, no. 7, pp. 759-765. https://doi.org/10.1179/1743132811Y.0000000006
Chaichana, Kaisorn L. ; Zaidi, Hasan ; Pendleton, Courtney ; McGirt, Matthew J. ; Grossman, Rachel ; Weingart, Jon D. ; Olivi, Alessandro ; Quinones-Hinojosa, Alfredo ; Brem, Henry. / The efficacy of carmustine wafers for older patients with glioblastoma multiforme : Prolonging survival. In: Neurological Research. 2011 ; Vol. 33, No. 7. pp. 759-765.
@article{cba3f97e898b404ab7fa9962a86989ee,
title = "The efficacy of carmustine wafers for older patients with glioblastoma multiforme: Prolonging survival",
abstract = "Objective: Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients. Methods: One hundred and thirty-three consecutive patients aged 65 years and older who underwent surgery for an intracranial primary (de novo) GBM from 1997-2007 were retrospectively reviewed. Among these 133 patients, 45 patients with carmustine wafer implantation were matched with 45 patients without implantation. These groups were matched for factors consistently shown to be associated with survival (age, Karnofsky performance scale, extent of resection, radiation therapy, and temozolomide). Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves. Variables with P<0.05 were considered statistically significant. Results: The mean (±standard deviation) age of the cohort was 73±5 years, and the median survival of the entire cohort was 5.9 months. Among patients with and without carmustine wafers, there were no significant differences in pre- and peri-operative variables. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007). Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers. Discussion: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.",
keywords = "Carmustine wafers, Elderly, GBM, Gliadel, Glioblastoma, Survival",
author = "Chaichana, {Kaisorn L.} and Hasan Zaidi and Courtney Pendleton and McGirt, {Matthew J.} and Rachel Grossman and Weingart, {Jon D.} and Alessandro Olivi and Alfredo Quinones-Hinojosa and Henry Brem",
year = "2011",
month = "9",
doi = "10.1179/1743132811Y.0000000006",
language = "English (US)",
volume = "33",
pages = "759--765",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "7",

}

TY - JOUR

T1 - The efficacy of carmustine wafers for older patients with glioblastoma multiforme

T2 - Prolonging survival

AU - Chaichana, Kaisorn L.

AU - Zaidi, Hasan

AU - Pendleton, Courtney

AU - McGirt, Matthew J.

AU - Grossman, Rachel

AU - Weingart, Jon D.

AU - Olivi, Alessandro

AU - Quinones-Hinojosa, Alfredo

AU - Brem, Henry

PY - 2011/9

Y1 - 2011/9

N2 - Objective: Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients. Methods: One hundred and thirty-three consecutive patients aged 65 years and older who underwent surgery for an intracranial primary (de novo) GBM from 1997-2007 were retrospectively reviewed. Among these 133 patients, 45 patients with carmustine wafer implantation were matched with 45 patients without implantation. These groups were matched for factors consistently shown to be associated with survival (age, Karnofsky performance scale, extent of resection, radiation therapy, and temozolomide). Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves. Variables with P<0.05 were considered statistically significant. Results: The mean (±standard deviation) age of the cohort was 73±5 years, and the median survival of the entire cohort was 5.9 months. Among patients with and without carmustine wafers, there were no significant differences in pre- and peri-operative variables. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007). Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers. Discussion: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.

AB - Objective: Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients. Methods: One hundred and thirty-three consecutive patients aged 65 years and older who underwent surgery for an intracranial primary (de novo) GBM from 1997-2007 were retrospectively reviewed. Among these 133 patients, 45 patients with carmustine wafer implantation were matched with 45 patients without implantation. These groups were matched for factors consistently shown to be associated with survival (age, Karnofsky performance scale, extent of resection, radiation therapy, and temozolomide). Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves. Variables with P<0.05 were considered statistically significant. Results: The mean (±standard deviation) age of the cohort was 73±5 years, and the median survival of the entire cohort was 5.9 months. Among patients with and without carmustine wafers, there were no significant differences in pre- and peri-operative variables. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007). Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers. Discussion: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.

KW - Carmustine wafers

KW - Elderly

KW - GBM

KW - Gliadel

KW - Glioblastoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=79960494838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960494838&partnerID=8YFLogxK

U2 - 10.1179/1743132811Y.0000000006

DO - 10.1179/1743132811Y.0000000006

M3 - Article

C2 - 21756557

AN - SCOPUS:79960494838

VL - 33

SP - 759

EP - 765

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 7

ER -